drugset / Trial / NCT05564117

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

NCT05564117

Phase 3 Completed 307 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks of treatment period and 7 weeks of follow up period.

Timeline

Start
2022-10-11
Primary completion
2024-04-18
Completion
2024-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 25 mg Oral

Indications